- Business segment: Services
- HTCR-Services GmbH
- Am Klopferspitz 19
- 82152 Planegg/Martinsried
- Phone: +49 (0)89/4400 76442
- Fax: +49 (0)89/520 596 95
Dr. Liming Ge, CEO
Founded in 2002 with the name Hepacult as a spin-off from the University of Regensburg, HTCR-Services provides human tissue-based products and services for medical research and drug development to academic research institutions and pharmaceutical companies across Europe. At the end of 2019 Hepacult became the wholly owned subsidiary of non-profit foundation HTCR (Human Tissue and Cell Research). As the exclusive service provider for the foundation, the new company name, HTCR-Services, is designed to reflect this fact. With access to a network of hospitals and leading surgeons, HTCR-Services provides broad range of diseased or normal tissues and other biospecimens (e.g. blood samples or PBMC) from the same donor that match the requirements of the researchers, accelerating the discovery of new disease-related markers and molecular diagnostics, target validations, and development of new drugs and treatment options.
What is your motivation?
It is an honor and our responsibility to make the invaluable human tissue available to the broad medical research community industrial and academic alike on behalf of patients who suffer from various oncological and inflammatory illnesses, so our partners can understand these illnesses better and will develop better treatment options for the future.
“IZB is an ideal place for small service companies like us. IZB management team is responsive to our various needs. We feel that we are in the good and competent hands.”
Dr. Liming Ge, CEO
HTCR-Services GmbH (formerly ”Hepacult GmbH“) is a wholly-owned subsidiary of the Human Tissue and Cell Research (HTCR) Foundation and supports the foundation’s mission to provide human tissue on a broad basis for research purposes. Originally founded as a spin-off from the University of Regensburg in 2002, HTCR-Services offers researchers products and services based on human tissue for medical research and drug development in academic research institutions and pharmaceutical companies in Europe.
Through its network of hospitals and senior surgeons, HTCR-Services offers a broad spectrum of pathological and/or healthy tissues with corresponding biospecimens (e.g. blood or PBMCs), to accelerate research to discover new diagnostic markers, validate targets and develop new drugs and therapies.